Abstract: The instant invention describes a method for establishing the hemostatic competence of blood, wherein the steps of the method include obtaining a blood sample from a subject, contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin in the blood sample at a pre-determined time point. The invention also describes a method for testing the capacity of an individual subject to produce thrombin, wherein the steps of the method include obtaining a blood sample from the subject; contacting the blood sample with an effective amount of tissue factor under conditions conducive to coagulating blood; and detecting the amount of thrombin produced in the blood sample at a pre-determined time point.

Abstract: Disclosed are compositions for treating blood coagulation disorders and allows for manipulation of the blood coagulation cascade. More particularly the invention, relates to compositions for altering bleeding that include a mixture of at least one blood coagulation factor in a low dose and phospholipid vesicles. The invention has a variety of important uses including controlling bleeding in a mammal that has or is suspected of having a potentially life-threatening blood coagulation disorder.

Abstract: This invention demonstrates the feasibility of producing an easy to use, marketable global test in the arena of clinical haemostasis testing that is sensitive to antithrombotic drugs, bleeding disorders and thrombotic pathologies. Use of this assay will provide insight into what predisposes an “apparently” healthy individual to thrombose, what effect does known risk factors (i.e. birth control/hormone replacement therapy) have on thrombin generation and whether certain individuals be excluded from specific therapies because of an underlying genetic abnormality, among other things.